Trial intelligence / Profile preview

Cinaciguat in acute decompensated chronic congestive heart failure

2009-017082-39Phase 2Terminated

Sponsor
Bayer
Start
Dec 2009
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of cinaciguat in chronic heart failure (CHF) and heart failure (HF) (4 arms), sponsored by Bayer. Primary endpoint: Change from baseline to 8 hours on Dyspnea VAS. Started Dec 2009; status: terminated.

02

Drugs

cinaciguat
03

Conditions

chronic heart failure (CHF)heart failure (HF)

Beyond the preview

Go deeper on 2009-017082-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-017082-39.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call